Actimed Therapeutics Ltd will put some of its additional funding of £4.75 million ($6 million) towards its attempt to provide the world’s first cure for cancer cachexia.
The Danish-US biotech Hemab Therapeutics bags $135m to finance the clinical development of prophylactic treatments for genetic bleeding disorders including Glanzmann thrombasthenia and von Willebrand disease.
